insights_auto
Hvorfor har ALNY gått ned? 4,96%?
Gå mer i dybdenchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
219,72 USD
arrow_downward
−4,96%(−11,46) 1 D
2. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for ALNY …
Åpne
231,31 USD
Høy
231,36 USD
Lav
219,40 USD
Markedsverdi
29,40 mrd.
Snittvolum
1,55 mill.
Volum
168,00
P/E-forhold
37,40
52 u høy
495,55 USD
52 u lav
197,81 USD
EPS
5,88 USD
Beta
0,28
Utestående aksjer
133,81 mill.
Antall ansatte
2k
Åpne
231,31 USD
Høy
231,36 USD
Lav
219,40 USD
Markedsverdi
29,40 mrd.
Snittvolum
1,55 mill.
Volum
168,00
P/E-forhold
37,40
52 u høy
495,55 USD
52 u lav
197,81 USD
EPS
5,88 USD
Beta
0,28
Utestående aksjer
133,81 mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Trefis
·
for 2 timer siden
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14%
Simply Wall Street
·
for 3 døgn siden
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Om Alnylam Pharmaceuticals, Inc.